Plasma antiretroviral levels in children with human immunodeficiency virus infection. Influence of sex and age;Niveles plasmáticos de antirretrovirales en niños con infección por el virus de la inmunodeficiencia humana. Influencia del género y de la edad

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 28, Issue 5, 2010, Pages 278-283

  Nso Roca, Ana Pilar ^a   Larru, Beatriz ^b   Bellón, Joséè María ^b   Mellado, María José ^a   Ramos, José Toms ^c   González, María Isabel ^d   Navarro, María Luisa ^b   Muñoz Fernndez, María Ángeles ^b,e   De José, María Isabel ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e CSIC   (Spain)

Author keywords

Antiretroviral concentrations; Children; Human immunodeficiency virus; Therapeutic drug monitoring

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; TIPRANAVIR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANALYSIS OF VARIANCE; ARTICLE; CHILD; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; LABORATORY TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MAXIMUM PLASMA CONCENTRATION; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SEX RATIO; VIRUS ACTIVATION; VIRUS LOAD; AGE; BLOOD; CLINICAL TRIAL; HIV INFECTIONS; MULTICENTER STUDY; SEX DIFFERENCE;

AGE FACTORS; ANTI-RETROVIRAL AGENTS; CHILD; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 77952287586     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2009.09.004     Document Type: Article

References (30)

1. M. De Martino, P.A. Tovo, M. Balducci, L. Galli, C. Gabiano, and G. Rezza Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 284 2000 190 197
2. E. Ribera, L.F. López-Corts, V. Soriano, J.L. Casado, and J. Mallolas Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: Can they be applied to the current situation? Enferm Infecc Microbiol Clin 23 2005 55 67
3. M. Sarasa-Nacenta, Y. López-Pua, J. Mallolas, J.L. Blanco, J.M. Gatell, and X. Carne Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography J Chromatogr B Biomed Sci Appl 757 2001 325 332
4. J.C. Slish, L.M. Catanzaro, Q. Ma, O.O. Okusanya, L. Demeter, and M. Albrecht Update on the pharmacokinetic aspects of antiretroviral agents: Implications in therapeutic drug monitoring Curr Pharm Des 12 2006 1129 1145
5. A.M. Van Rossum, R. de Groot, N.G. Hartwig, C.M. Weemaes, S. Head, and D.M. Burger Pharmacokinetics of indinavir and low-dose ritonavir in children with HIV-1 infection AIDS 14 2000 2209 2210
6. L.C. Floren, A. Wiznia, S. Hayashi, A. Jayewardene, K. Stanley, and G. Johnson Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377 Pediatrics 112 2003 e220 e227
7. D.E. Morisky, L.W. Green, and D.M. Levine Concurrent and predictive validity of a self-reported measure of medication adherence Med Care 24 1986 67 74
8. ONUSIDA, OMS. Situacin de la epidemia de sida. [consultado 28/6/2009]. Disponible en: http://data.unaids.org/pub/EPISlides/2007/2007-epiupdate-es.pdf ; 2007.
9. P.L. Fraaij, J.J. Van Kampen, D.M. Burger, and R. De Groot Pharmacokinetics of antiretroviral therapy in HIV-1-infected children Clin Pharmacokinet 44 2005 935 956
10. P.L. Fraaij, A.S. Bergshoeff, A.M. Van Rossum, N.G. Hartwig, D.M. Burger, and R. De Groot Changes in indinavir exposure over time: A case study in six HIV-1-infected children J Antimicrob Chemother 52 2003 727 730
11. R.P. Van Heeswijk, H.J. Scherpbier, L.A. De Koning, H.S. Heymans, J.M. Lange, and J.H. Beijnen The pharmacokinetics of nelfinavir in HIV-1-infected children Ther Drug Monit 24 2002 487 491
12. D.M. Burger, A.S. Bergshoeff, R. De Groot, D. Gibb, S. Walker, and J.M. Treluyer Maintaining the nelfinavir trough concentration above 0.8 mg/l improves virologic response in HIV-1-infected children J Pediatr 145 2004 403 405
13. D. Dunn Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: A meta-analysis Lancet 362 2003 1605 1611
14. rd, J. Bethel, K. Rich, and S. Pahwa The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group J Infect Dis 175 1997 1029 1038
15. A.M. Van Rossum, P.L. Fraaij, and R. De Groot Efficacy of highly active antiretroviral therapy in HIV-1 infected children Lancet Infect Dis 2 2002 93 102
16. N.Y. Rakhmanina, J.N. Van den Anker, and S.J. Soldin Therapeutic drug monitoring of antiretroviral therapy AIDS Patient Care STDS 18 2004 7 14
17. C.V. Fletcher, R.C. Brundage, R.P. Remmel, L.M. Page, D. Weller, and N.R. Calles Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy Antimicrob Agents Chemother 44 2000 1029 1034
18. U. Wintergerst, F. Hoffmann, A. Jansson, G. Notheis, K. Huss, and M. Kurowski Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children J Antimicrob Chemother 61 2008 1336 1339
19. E.V. Capparelli, J.L. Sullivan, L. Mofenson, E. Smith, B. Graham, and P. Britto Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants Pediatr Infect Dis J 20 2001 746 751 (Pubitemid 32758015)
20. S. Rodrguez-Novoa, J. Morello, P. Barreiro, I. Maida, P. Garca-Gasco, and E. Vispo Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring AIDS Res Hum Retroviruses 24 2008 821 825
21. J. Molto, J.R. Santos, M. Valle, C. Miranda, J. Miranda, and A. Blanco Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice Ther Drug Monit 29 2007 648 651
22. J. Molto, A. Blanco, C. Miranda, J. Miranda, J. Puig, and M. Valle Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice Br J Clin Pharmacol 63 2007 715 721
23. J.L. Casado, A. Moreno, R. Sabido, P. Marti-Belda, A. Antela, and F. Dronda A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: Influence of increased plasma drug levels in the rate of response HIV Clin Trials 1 2000 13 19
24. Y. Ren, J.J. Nuttall, C. Egbers, B.S. Eley, T.M. Meyers, and P.J. Smith High prevalence of subtherapeutic plasma concentrations of efavirenz in children J Acquir Immune Defic Syndr 45 2007 133 136
25. C. Solas, S. Basso, I. Poizot-Martin, I. Ravaux, H. Gallais, and J.A. Gastaut High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen J Acquir Immune Defic Syndr 29 2002 374 377
26. P. Langmann, M. Zilly, B. Weissbrich, S. Desch, T. Vath, and H. Klinker Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART Infection 30 2002 13 16
27. I. Pellegrin, D. Breilh, F. Montestruc, A. Caumont, I. Garrigue, and P. Morlat Virologic response to nelfinavir-based regimens: Pharmacokinetics and drug resistance mutations (VIRAPHAR study) AIDS 16 2002 1331 1340
28. S.A. Danner, A. Carr, J.M. Leonard, L.M. Lehman, F. Gudiol, and J. Gonzles A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group N Engl J Med 333 1995 1528 1533
29. C. Marzolini, A. Telenti, L.A. Decosterd, G. Greub, J. Biollaz, and T. Buclin Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients AIDS 15 2001 71 75 (Pubitemid 32055781)
30. A.I. Veldkamp, G.J. Weverling, J.M. Lange, J.S. Montaner, P. Reiss, and D.A. Cooper High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals AIDS 15 2001 1089 1095